Modulation of antimicrobial resistance in clinical isolates of Enterobacter aerogenes: A strategy combining antibiotics and chemosensitisers

Matthew P. McCusker, Daniela Alves Ferreira, Donal Cooney, Bruno Martins Alves, Seámus Fanning, Jean Marie Pagès, Marta Martins, Anne Davin-Regli*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Citations (Scopus)

Abstract

Objective: The main focus of this study was to evaluate the antimicrobial susceptibility profiles of a number of human clinical isolates of Enterobacter aerogenes isolates and to explore the effects of selected chemosensitisers on reversal of the resistant phenotype of these isolates. 

Methods: This study design was accomplished by: (i) characterising several multidrug-resistant (MDR) E. aerogenes clinical isolates; (ii) evaluating the contribution of target gene mutations to the resistance phenotype, focusing on fluoroquinolones and chloramphenicol only; (iii) evaluating the contribution of membrane permeability and efflux to the MDR phenotype; (iv) assessing the combined action of selected antimicrobials and chemosensitisers in order to identify combinations with synergistic effects able to reduce the minimum inhibitory concentration (MIC); and (v) understanding how these combinations can modulate the permeability or efflux of these isolates. 

Results: Resistance to ciprofloxacin could not be totally reversed owing to pre-existing mutations in target genes. Chloramphenicol susceptibility was efficiently restored by the addition of the selected chemosensitisers. From the modulation kinetics it was clear that phenothiazines were able to increase the accumulation of Hoechst dye. 

Conclusions: Modulation of permeability and efflux in the presence of chemosensitisers can help us to propose more appropriate chemotherapeutic combinations that can set the model to be used in the treatment of these and other MDR infections.

Original languageEnglish
Pages (from-to)187-198
Number of pages12
JournalJournal of global antimicrobial resistance
Volume16
Early online date08 Feb 2019
DOIs
Publication statusPublished - Mar 2019
Externally publishedYes

Bibliographical note

Funding Information:
The research leading to the results discussed here was conducted as part of the Translocation Consortium (http://www.translocation.eu) and has received support from the Innovative Medicines joint Undertaking [grant agreement no. 115525], resources which are composed of financial contribution from the European Union's Seventh Framework Programme [FP/2007-2013] and EFPIA companies in kind contributions. This work was also partly supported by the Agence Nationale de la Recherche (ANR, France) [grant ANR-11-BS07-019-0]. MPM was partially supported by the Dawn Farm Foods Newman Fellowship in Food Safety. MM was partially supported by the Vétoquinol SA Newman Fellowship in Food Safety.

Funding Information:
The research leading to the results discussed here was conducted as part of the Translocation Consortium ( http://www.translocation.eu ) and has received support from the Innovative Medicines joint Undertaking [grant agreement no. 115525 ], resources which are composed of financial contribution from the European Union’s Seventh Framework Programme [ FP/2007-2013 ] and EFPIA companies in kind contributions. This work was also partly supported by the Agence Nationale de la Recherche (ANR, France) [grant ANR-11-BS07-019-0 ]. MPM was partially supported by the Dawn Farm Foods Newman Fellowship in Food Safety . MM was partially supported by the Vétoquinol SA Newman Fellowship in Food Safety .

Publisher Copyright:
© 2018 International Society for Chemotherapy of Infection and Cancer

Keywords

  • Chemosensitisers
  • Combination therapy
  • Efflux pump
  • Fluoroquinolones
  • Multidrug resistance
  • Permeability

ASJC Scopus subject areas

  • Microbiology
  • Immunology and Allergy
  • Immunology
  • Microbiology (medical)

Fingerprint

Dive into the research topics of 'Modulation of antimicrobial resistance in clinical isolates of Enterobacter aerogenes: A strategy combining antibiotics and chemosensitisers'. Together they form a unique fingerprint.

Cite this